Analyst Reco. Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Real-time Estimate Tradegate Other stock markets 10:39:04 2024-05-17 EDT			5-day change	1st Jan Change
1.891 ^EUR	-10.21%		+18.82%	-77.97%

05-15	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	MT
05-15	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	05-15	MT
Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating	05-13	MT
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	04-22	MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	04-18	MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	04-18	MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	04-17	MT
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	04-10	MT
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating	02-16	MT
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating	01-02	MT
Guggenheim Initiates Pacific Biosciences of California With Neutral Rating	12-14	MT
UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13	11-17	MT
Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating	11-06	MT
Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14	23-10-31	MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating	23-10-24	MT
Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating	23-09-29	MT
Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target	23-09-28	MT
UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating	23-08-04	MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating	23-08-03	MT
Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target	23-06-30	MT
Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating	23-06-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Analyst Reco.

Filters